TF
TruthOrFake
Fact Check: TTAM Research Institute will acquire substantially all of 23andMe’s assets, including its Personal Genome Service and Research Services business lines as well as telehealth subsidiary Lemonaid Health.

Fact Check: TTAM Research Institute will acquire substantially all of 23andMe’s assets, including its Personal Genome Service and Research Services business lines as well as telehealth subsidiary Lemonaid Health.

June 15, 2025•by TruthOrFake AI
✓
VERDICT
True

# Fact Check: TTAM Research Institute Will Acquire Substantially All of 23andMe’s Assets ## What We Know The claim that "TTAM Research Institute will...

Fact Check: TTAM Research Institute Will Acquire Substantially All of 23andMe’s Assets

What We Know

The claim that "TTAM Research Institute will acquire substantially all of 23andMe’s assets, including its Personal Genome Service and Research Services business lines as well as telehealth subsidiary Lemonaid Health" is supported by multiple credible sources. According to NBC News, TTAM Research Institute, led by Anne Wojcicki, has successfully bid $305 million to acquire these assets from 23andMe, which recently filed for Chapter 11 bankruptcy. The acquisition includes significant components of the company, such as its Personal Genome Service and Research Services, along with its telehealth subsidiary, Lemonaid Health.

Additionally, CNN corroborates this information, stating that TTAM will acquire "substantially all" of 23andMe's assets, confirming the inclusion of the Personal Genome Service and Research Services business lines, as well as Lemonaid Health.

Analysis

The evidence supporting the claim comes from reputable news outlets that have reported on the acquisition process. NBC News and CNN are both established media organizations known for their journalistic standards, which lends credibility to their reporting. The acquisition is described as a significant development in the context of 23andMe's financial struggles, including its bankruptcy filing and previous attempts by Regeneron Pharmaceuticals to purchase the company for $256 million, which TTAM ultimately outbid (source-1, source-2).

Moreover, the acquisition's details are further confirmed by GlobeNewswire, which outlines the terms of the sale and reiterates that TTAM will continue to uphold 23andMe's privacy policies regarding customer data rights. This is crucial given the concerns surrounding data privacy that have emerged during 23andMe's financial difficulties.

While the information from these sources is consistent, it is essential to note that the deal is still subject to approval by the U.S. Bankruptcy Court for the Eastern District of Missouri, indicating that while the acquisition is planned, it is not yet finalized (source-1, source-2).

Conclusion

Verdict: True
The claim that TTAM Research Institute will acquire substantially all of 23andMe’s assets, including its Personal Genome Service, Research Services business lines, and telehealth subsidiary Lemonaid Health, is accurate. This conclusion is based on multiple reliable sources confirming the details of the acquisition and the specific assets involved. The acquisition is a significant development for both TTAM and 23andMe, especially in light of the latter's recent financial challenges.

Sources

  1. Anne Wojcicki to buy back 23andMe and its data for $305 million - NBC News
  2. Anne Wojcicki's nonprofit wins bid to acquire genetic testing company - CNN
  3. 23andMe Reaches Agreement for Sale of Business to TTAM - GlobeNewswire
  4. 23andMe Reaches Agreement for Sale of Business to TTAM - 23andMe Investor Relations
  5. 23andMe co-founder Anne Wojcicki has bought back the company - NewsBytes
  6. Anne Wojcicki, the co-founder and former CEO of 23andMe - LinkedIn
  7. Anne Wojcicki's nonprofit reaches deal to acquire 23andMe - TechCrunch
  8. 23andMe assets to be sold to founder's nonprofit for $305 million - Investing.com

Have a claim you want to verify? It's 100% Free!

Our AI-powered fact-checker analyzes claims against thousands of reliable sources and provides evidence-based verdicts in seconds. Completely free with no registration required.

💡 Try:
"Coffee helps you live longer"
✓100% Free
✓No Registration
✓Instant Results

Comments

Comments

Leave a comment

Loading comments...

More Fact Checks to Explore

Discover similar claims and stay informed with these related fact-checks

Fact Check: TTAM Research Institute will acquire substantially all of 23andMe’s assets for $305 million, including its Personal Genome Service and Research Services business lines as well as telehealth subsidiary Lemonaid Health.
True
🎯 Similar

Fact Check: TTAM Research Institute will acquire substantially all of 23andMe’s assets for $305 million, including its Personal Genome Service and Research Services business lines as well as telehealth subsidiary Lemonaid Health.

Detailed fact-check analysis of: TTAM Research Institute will acquire substantially all of 23andMe’s assets for $305 million, including its Personal Genome Service and Research Services business lines as well as telehealth subsidiary Lemonaid Health.

Jun 15, 2025
Read more →
Fact Check: TTAM Research Institute will acquire substantially all of 23andMe’s assets, including its Personal Genome Service and telehealth subsidiary Lemonaid Health.
True
🎯 Similar

Fact Check: TTAM Research Institute will acquire substantially all of 23andMe’s assets, including its Personal Genome Service and telehealth subsidiary Lemonaid Health.

Detailed fact-check analysis of: TTAM Research Institute will acquire substantially all of 23andMe’s assets, including its Personal Genome Service and telehealth subsidiary Lemonaid Health.

Jun 14, 2025
Read more →
Fact Check: Anne Wojcicki, the co-founder and former CEO of 23andMe, regained control of the company after her nonprofit, TTAM Research Institute, outbid Regeneron Pharmaceuticals for $305 million.
True
🎯 Similar

Fact Check: Anne Wojcicki, the co-founder and former CEO of 23andMe, regained control of the company after her nonprofit, TTAM Research Institute, outbid Regeneron Pharmaceuticals for $305 million.

Detailed fact-check analysis of: Anne Wojcicki, the co-founder and former CEO of 23andMe, regained control of the company after her nonprofit, TTAM Research Institute, outbid Regeneron Pharmaceuticals for $305 million.

Jun 14, 2025
Read more →
🔍
True

Fact Check: Business leaders and ex bank heads throw support behind Poilievre A number of prominent business leaders formally threw their support behind Pierre Poilievre in the upcoming federal election on Saturday, arguing his Conservative Party will best handle Canada’s slowing economic growth. The group of more than 30 current and past executives includes Fairfax Financial CEO Prem Watsa, Canaccord Genuity CEO Dan Daviau, former RBC Capital Markets CEO Anthony Fell and former Scotiabank CEO Brian Porter. They published an open letter in several Canadian newspapers on Saturday saying Poilievre's plans are best to get the country's economy "back on track." "Productivity has stalled. Economic growth has slowed. Our GDP per capita is shrinking," the letter reads. "Nevertheless, this decline is not inevitable -- and it's not the Canada we know and love." To turn things around, the letter said Canada needs to eliminate barriers to productivity by streamlining permit processes and cutting outdated regulations that prevent investment and job creation. It also said the government needs to be more disciplined with its spending, impose lower taxes to make Canada more competitive and develop the country's natural resources by building pipelines, expanding mining and investing in energy. The letter, which was also signed by former RioCan Real Estate Investment Trust founder Edward Sonshine, Mattamy Homes CEO Peter Gilgan and past Toronto Blue Jays president Paul Godfrey, is one of the strongest shows of support Poilievre has seen from the business community yet. His competitor, Liberal Mark Carney, has spent much of the election campaign, which concludes on April 28 when Canadians go to the polls, touting his experience as leader of the central banks in both Canada and England. He argues that experience leaves him best equipped to address the country's economic woes and tariff threats from U.S. President Donald Trump. The Liberals did not immediately respond to request for comment on the letter. The Conservatives, however, took the missive as a sign that their platform is resonating with the business community. “Pierre Poilievre’s Canada First Economic Action Plan is being recognized as a strong plan to lower taxes and eliminate red tape to unleash our industries and bring home powerful paycheques for our people and a thriving economy," Conservative spokesman Sam Lilly said in a statement. Poilievre revealed earlier this week that his plan is designed to cut bureaucratic red tape by 25 per cent in two years through a "two-for-one" law. The law would see two regulations be repealed for every new one that's enacted and require that every dollar spent on new administrative costs trigger the cutting of two dollars in other areas. Meanwhile, Carney has said he will boost interprovincial trade by removing all exemptions under the Canadian Free Trade Agreement, develop a new fund to help link natural resource extraction sites with rail lines and roads and create new programs geared toward training workers. NDP Leader Jagmeet Singh said it was "no surprise" some business leaders are backing Poilievre and Carney because they're giving a tax break to the ultra-wealthy," rather than focusing on "what people actually need—health care, housing, and support when they lose a job." "Canadians are working hard but falling behind," Singh said in a statement. "Wages aren’t keeping up, housing is out of reach, and public services are stretched. The economy isn’t working for most people." This report by The Canadian Press was first published April 12, 2025. Tara Deschamps, The Canadian Press

Detailed fact-check analysis of: Business leaders and ex bank heads throw support behind Poilievre A number of prominent business leaders formally threw their support behind Pierre Poilievre in the upcoming federal election on Saturday, arguing his Conservative Party will best handle Canada’s slowing economic growth. The group of more than 30 current and past executives includes Fairfax Financial CEO Prem Watsa, Canaccord Genuity CEO Dan Daviau, former RBC Capital Markets CEO Anthony Fell and former Scotiabank CEO Brian Porter. They published an open letter in several Canadian newspapers on Saturday saying Poilievre's plans are best to get the country's economy "back on track." "Productivity has stalled. Economic growth has slowed. Our GDP per capita is shrinking," the letter reads. "Nevertheless, this decline is not inevitable -- and it's not the Canada we know and love." To turn things around, the letter said Canada needs to eliminate barriers to productivity by streamlining permit processes and cutting outdated regulations that prevent investment and job creation. It also said the government needs to be more disciplined with its spending, impose lower taxes to make Canada more competitive and develop the country's natural resources by building pipelines, expanding mining and investing in energy. The letter, which was also signed by former RioCan Real Estate Investment Trust founder Edward Sonshine, Mattamy Homes CEO Peter Gilgan and past Toronto Blue Jays president Paul Godfrey, is one of the strongest shows of support Poilievre has seen from the business community yet. His competitor, Liberal Mark Carney, has spent much of the election campaign, which concludes on April 28 when Canadians go to the polls, touting his experience as leader of the central banks in both Canada and England. He argues that experience leaves him best equipped to address the country's economic woes and tariff threats from U.S. President Donald Trump. The Liberals did not immediately respond to request for comment on the letter. The Conservatives, however, took the missive as a sign that their platform is resonating with the business community. “Pierre Poilievre’s Canada First Economic Action Plan is being recognized as a strong plan to lower taxes and eliminate red tape to unleash our industries and bring home powerful paycheques for our people and a thriving economy," Conservative spokesman Sam Lilly said in a statement. Poilievre revealed earlier this week that his plan is designed to cut bureaucratic red tape by 25 per cent in two years through a "two-for-one" law. The law would see two regulations be repealed for every new one that's enacted and require that every dollar spent on new administrative costs trigger the cutting of two dollars in other areas. Meanwhile, Carney has said he will boost interprovincial trade by removing all exemptions under the Canadian Free Trade Agreement, develop a new fund to help link natural resource extraction sites with rail lines and roads and create new programs geared toward training workers. NDP Leader Jagmeet Singh said it was "no surprise" some business leaders are backing Poilievre and Carney because they're giving a tax break to the ultra-wealthy," rather than focusing on "what people actually need—health care, housing, and support when they lose a job." "Canadians are working hard but falling behind," Singh said in a statement. "Wages aren’t keeping up, housing is out of reach, and public services are stretched. The economy isn’t working for most people." This report by The Canadian Press was first published April 12, 2025. Tara Deschamps, The Canadian Press

Apr 13, 2025
Read more →
Fact Check: Regeneron Pharmaceuticals initially announced it would purchase most of 23andMe’s assets for $256 million before Wojcicki's TTAM submitted a higher bid.
True

Fact Check: Regeneron Pharmaceuticals initially announced it would purchase most of 23andMe’s assets for $256 million before Wojcicki's TTAM submitted a higher bid.

Detailed fact-check analysis of: Regeneron Pharmaceuticals initially announced it would purchase most of 23andMe’s assets for $256 million before Wojcicki's TTAM submitted a higher bid.

Jun 15, 2025
Read more →
Fact Check: Regeneron Pharmaceuticals initially announced a bid of $256 million for most of 23andMe’s assets before TTAM submitted a higher bid.
True

Fact Check: Regeneron Pharmaceuticals initially announced a bid of $256 million for most of 23andMe’s assets before TTAM submitted a higher bid.

Detailed fact-check analysis of: Regeneron Pharmaceuticals initially announced a bid of $256 million for most of 23andMe’s assets before TTAM submitted a higher bid.

Jun 14, 2025
Read more →
Explore All Fact Checks
Fact Check: TTAM Research Institute will acquire substantially all of 23andMe’s assets, including its Personal Genome Service and Research Services business lines as well as telehealth subsidiary Lemonaid Health. | TruthOrFake Blog